Treat in Germany
Plan treatment

Ophthalmology → Retinal Artery Occlusion (CRAO/BRAO)

Retinal vascular emergency

Retinal Artery Occlusion in Germany: CRAO/BRAO Emergency, Stroke Evaluation and Follow-Up

Emergency-first guidance for central or branch retinal artery occlusion, including sudden painless vision loss, urgent stroke evaluation, OCT and angiography, embolic-source work-up and giant-cell-arteritis red flags.

Sudden vision loss now? Do not travel.

Seek emergency care where you are immediately. Retinal artery occlusion can be a time-critical neurovascular emergency; stroke and ophthalmic evaluation must not be delayed for travel to Germany.

Priority: local emergency care

By Treat in Germany Editorial TeamSources reviewed: 2026-09-13Independent clinician review: not yet claimed
Short answer: Central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO) can cause sudden, usually painless visual loss and should be treated as urgent local medical problems rather than reasons to arrange international travel. UKE describes retinal arterial occlusion as requiring ophthalmic diagnosis plus neurological evaluation, often including a stroke-unit pathway and a search for embolic sources. If the visual loss is happening now or began recently, seek emergency care where you are and do not wait to travel to Germany.

Sudden persistent visual loss is an emergency

UKE describes central retinal artery occlusion as an acute interruption of the retinal arterial blood supply. The clinical pattern is commonly sudden, painless and persistent visual deterioration, sometimes with a major field defect. The UKE CRAO research program emphasizes that retinal ischemic injury develops rapidly and that emergency assessment should start immediately.

Do not delay stroke-style evaluation for medical travel

UKE lists neurological assessment, possible stroke-unit admission and a search for embolic sources as part of the pathway. Relevant systemic evaluation can include blood pressure measurement, carotid Doppler imaging, echocardiography and evaluation for transient ischemic attacks or amaurosis fugax. The German ophthalmology guideline from DOG/RG/BVA also covers CRAO, branch retinal artery occlusion and amaurosis fugax as one retinal arterial-occlusion spectrum.

Eye imaging confirms the retinal diagnosis and ischemic pattern

Fundus examination, OCT and fluorescein angiography can help document the arterial occlusion and retinal ischemia. These tests complement rather than replace the urgent neurological and vascular work-up because the underlying cause may have implications beyond the eye.

There is no guaranteed vision-restoring treatment

For non-arteritic CRAO, treatment evidence remains difficult and time-sensitive. UKE notes that reperfusion strategies such as thrombolysis have been studied in very early presentation. A 2026 randomized trial of tenecteplase given within 4.5 hours did not improve the primary visual-recovery outcome compared with aspirin and raised serious safety concerns. Decisions about any acute reperfusion treatment must therefore be made immediately by the local stroke/ophthalmology team according to the patient's timing, diagnosis, contraindications and current protocol—not by delaying care for travel.

Giant cell arteritis must be considered urgently when clinically plausible

In older patients, retinal arterial occlusion can occur in giant cell arteritis. UKE describes headache, jaw pain, scalp tenderness, constitutional symptoms and raised inflammatory markers among typical clues and states that giant cell arteritis with ocular vascular involvement is an emergency. When suspected, treatment should not be delayed while waiting for the full diagnostic work-up.

What matters after the acute phase

Once emergency management is complete, follow-up should address both the eye and the systemic vascular cause. A later German second opinion may be useful for reviewing imaging, confirming the retinal diagnosis, assessing complications or discussing rehabilitation, but it should never replace the initial emergency pathway.

  • Exact time of onset and whether vision loss was sudden or transient
  • Fundus photographs and macular OCT
  • Fluorescein angiography if performed
  • Visual acuity and visual-field findings
  • Carotid imaging and cardiac evaluation
  • Stroke-unit or neurology discharge summary
  • Blood pressure and vascular risk-factor history
  • Inflammatory markers and giant-cell-arteritis evaluation when relevant
  • Current antiplatelet, anticoagulant and cardiovascular medication

Official and current sources

Medical information notice: General educational information, not an individual diagnosis. With new sudden visual loss, local emergency care takes priority.
Send treatment request